{"id":"NCT01830543","sponsor":"Janssen Scientific Affairs, LLC","briefTitle":"A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention","officialTitle":"An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-05-10","primaryCompletion":"2016-07-28","completion":"2016-07-28","firstPosted":"2013-04-12","resultsPosted":"2017-07-31","lastUpdate":"2017-09-19"},"enrollment":2124,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Atrial Fibrillation","Percutaneous Coronary Intervention"],"interventions":[{"type":"DRUG","name":"rivaroxaban 2.5 mg","otherNames":[]},{"type":"DRUG","name":"rivaroxaban 15 mg","otherNames":[]},{"type":"DRUG","name":"rivaroxaban 10 mg","otherNames":[]},{"type":"DRUG","name":"aspirin (ASA)","otherNames":[]},{"type":"DRUG","name":"vitamin K antagonist (VKA)","otherNames":[]},{"type":"DRUG","name":"clopidogrel","otherNames":[]},{"type":"DRUG","name":"prasugrel","otherNames":[]},{"type":"DRUG","name":"ticagrelor","otherNames":[]}],"arms":[{"label":"rivaroxaban 2.5 mg twice daily","type":"EXPERIMENTAL"},{"label":"vitamin K antagonist (VKA)","type":"EXPERIMENTAL"},{"label":"rivaroxaban 15 mg once daily","type":"EXPERIMENTAL"}],"summary":"The primary purpose of this study is to evaluate the safety for 2 different rivaroxaban treatment strategies and one Vitamin K Antagonist (VKA) treatment strategy utilizing various combinations of dual antiplatelet therapy (DAPT) or low-dose aspirin (ASA) or clopidogrel (or prasugrel or ticagrelor).","primaryOutcome":{"measure":"Percentage of Participants With Clinically Significant Bleeding","timeFrame":"Up to Month 12","effectByArm":[{"arm":"Rivaroxaban 15 mg","deltaMin":15.7,"sd":null},{"arm":"Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)","deltaMin":16.6,"sd":null},{"arm":"Vitamin K Antagonist (VKA)","deltaMin":24,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":348,"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","Canada","Chile","Czechia","Denmark","France","Germany","Malaysia","Mexico","Netherlands","Poland","Romania","Russia","South Africa","South Korea","Sweden","Taiwan","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["31707805","31535314","30704287","30015064","29943350","29550085","27959713","27881555","25819853"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":237,"n":696},"commonTop":["Epistaxis","Haematoma","Contusion","Dyspnoea","Gingival Bleeding"]}}